- Home
- VIGL vs TELA Comparison
VIGL vs TELA Comparison
Compare VIGL & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- TELA
- Stock Information
- Founded
- VIGL 2020
- TELA 2012
- Country
- VIGL United States
- TELA United States
- Employees
- VIGL N/A
- TELA N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- TELA Medical/Dental Instruments
- Sector
- VIGL Health Care
- TELA Health Care
- Exchange
- VIGL Nasdaq
- TELA Nasdaq
- Market Cap
- VIGL 89.3M
- TELA 92.2M
- IPO Year
- VIGL 2022
- TELA 2019
- Fundamental
- Price
- VIGL $1.68
- TELA $1.27
- Analyst Decision
- VIGL Strong Buy
- TELA Strong Buy
- Analyst Count
- VIGL 5
- TELA 4
- Target Price
- VIGL $16.33
- TELA $6.00
- AVG Volume (30 Days)
- VIGL 159.5K
- TELA 414.2K
- Earning Date
- VIGL 03-13-2025
- TELA 03-20-2025
- Dividend Yield
- VIGL N/A
- TELA N/A
- EPS Growth
- VIGL N/A
- TELA N/A
- EPS
- VIGL N/A
- TELA N/A
- Revenue
- VIGL N/A
- TELA $69,300,000.00
- Revenue This Year
- VIGL N/A
- TELA $38.03
- Revenue Next Year
- VIGL N/A
- TELA $24.38
- P/E Ratio
- VIGL N/A
- TELA N/A
- Revenue Growth
- VIGL N/A
- TELA 18.56
- 52 Week Low
- VIGL $1.49
- TELA $1.15
- 52 Week High
- VIGL $6.06
- TELA $6.50
- Technical
- Relative Strength Index (RSI)
- VIGL 32.05
- TELA 23.43
- Support Level
- VIGL $1.74
- TELA $1.15
- Resistance Level
- VIGL $1.94
- TELA $1.37
- Average True Range (ATR)
- VIGL 0.16
- TELA 0.18
- MACD
- VIGL -0.02
- TELA -0.08
- Stochastic Oscillator
- VIGL 4.51
- TELA 9.38
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About TELA TELA Bio Inc.
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.